Parental preference of prandial insulin aspart compared with preprandial human insulin in a basal-bolus scheme with NPH insulin in a 12-wk crossover study of preschool children with type 1 diabetes

被引:32
|
作者
Danne, Thomas
Rastam, Jacob
Odendahl, Rainer
Naeke, Andrea
Schimmel, Ulf
Szczepanski, Ruediger
Moeller, Johannes
Deiss, Dorothea
机构
[1] Kinderkrankenhaus auf Bult, D-30173 Hannover, Germany
[2] NovoNordisk AS, Bagsvaerd, Denmark
[3] Univ Schleswig Holstein Klinikum, Klin Kinder & Jugendmed, Lubeck, Germany
[4] Universitatskinderklin TU, Dresden, Germany
[5] Kinderklin Hagen, Hagen, Germany
[6] Kinderhosp, Osnabruck, Germany
[7] NovoNordisk GmbH, Mainz, Germany
[8] Charite, Klin Allgemeine Padiat, Berlin, Germany
关键词
basal/bolus; insulin aspart; pediatric; postprandial; quality of life;
D O I
10.1111/j.1399-5448.2007.00261.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: Preprandial insulin injection in preschool children is complicated by irregular eating habits. Postprandial injection of rapid-acting insulin analogs such as insulin aspart (IAsp) offers the convenience of adjusting insulin dose to match food consumed. This trial compared safety and efficacy - including parental treatment satisfaction - of two basal-bolus regimens [IAsp plus Neutral Protein Hagedorn (NPH) insulin vs. regular human insulin (HI) plus NPH] in preschool children with type 1 diabetes. Methods: This study is a randomized, 12-wk, crossover trial comparing IAsp and regular HI in 26 children (17 boys and 9 girls; age: 2.4-6.9 yr). Regular HI was injected 30 min before and IAsp after or shortly before meals. Treatment satisfaction was assessed by a modified version of the WHO Diabetes Treatment Satisfaction Questionnaire (DTSQ-M). Results: Glycemic control for IAsp treatment was not different from that for regular HI treatment as assessed by mean postprandial blood glucose increment (IAsp vs. regular HI: 2.0 vs. 1.6 mmol/L), fructosamine (300 vs. 302 mu mol/L), and hemoglobin A(1c) (HbA(1c)) (7.7 vs. 7.6%). The relative risk of hypoglycemia was not significantly different [relative risk for IAsp/regular HI (95% CI): 1.06 (0.96-1.17), p = 0.225]. Mean total daily insulin dose (0.7 U/kg) remained constant throughout the trial with both treatments. The DTSQ-M score tended to be better for IAsp and reached statistical significance regarding the parental satisfaction with continuing IAsp treatment (p < 0.05). Conclusion: In preschool children, a basal-bolus treatment scheme with postprandial IAsp as bolus insulin was equally effective and safe compared with preprandial regular HI, although the parents showed a preference for the IAsp treatment.
引用
收藏
页码:278 / 285
页数:8
相关论文
共 50 条
  • [31] Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial
    Heller, Simon
    Buse, John
    Fisher, Miles
    Garg, Satish
    Marre, Michel
    Merker, Ludwig
    Renard, Eric
    Russell-Jones, David
    Philotheou, Areti
    Francisco, Ann Marie Ocampo
    Pei, Huiling
    Bode, Bruce
    [J]. LANCET, 2012, 379 (9825): : 1489 - 1497
  • [32] Cost-effectiveness of insulin degludec compared with insulin glargine in a basal-bolus regimen in patients with type 1 diabetes mellitus in the UK
    Evans, M.
    Wolden, M.
    Gundgaard, J.
    Chubb, B.
    Christensen, T.
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2015, 18 (01) : 56 - 68
  • [33] LOWER TREATMENT COSTS WITH INSULIN GLARGINE COMPARED TO INSULIN DETEMIR IN TYPE 1 DIABETES PATIENTS TREATED WITH A BASAL-BOLUS REGIMEN IN GERMANY
    Wiesner, T.
    Schaedlich, P. K.
    Dippel, F. W.
    Koltermann, K.
    Hagenmeyer, E. G.
    [J]. VALUE IN HEALTH, 2010, 13 (07) : A294 - A294
  • [34] Superior prandial glucose control with insulin aspart compared to regular human insulin in basal bolus therapy with NPH in patients with inadequately controlled T1DM or T2 DM
    Gao, Yan
    Pan, Changyu
    Zou, Dajin
    Xu, Zhangrong
    Liu, Xiaomin
    Guo, Xiaohui
    [J]. DIABETES, 2006, 55 : A464 - A464
  • [35] Double-blind mealtime faster-acting insulin aspart vs insulin aspart in basal-bolus improves glycaemic control in Type 1 diabetes: the onset 1 trial
    Russell-Jones, D.
    Bode, B. W.
    De Block, C.
    Franek, E.
    Heller, S.
    Mathieu, C.
    Philis-Tsimikas, A.
    Rose, L.
    Woo, V.
    Osterskov, A. B.
    Graungaard, T.
    Bergenstal, R.
    [J]. DIABETIC MEDICINE, 2017, 34 : 8 - 8
  • [36] Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN® Basal-Bolus Type 1): 2-year results of a randomized clinical trial
    Bode, B. W.
    Buse, J. B.
    Fisher, M.
    Garg, S. K.
    Marre, M.
    Merker, L.
    Renard, E.
    Russell-Jones, D. L.
    Hansen, C. T.
    Rana, A.
    Heller, S. R.
    [J]. DIABETIC MEDICINE, 2013, 30 (11) : 1293 - 1297
  • [37] COST-EFFECTIVENESS OF INSULIN DEGLUDEC COMPARED WITH INSULIN GLARGINE IN A BASAL-BOLUS REGIMEN IN PATIENTS WITH TYPE 1 DIABETES MELLITUS IN THE UNITED KINGDOM
    Chubb, B.
    Evans, M.
    Wolden, M.
    Christensen, T.
    Gundgaard, J.
    [J]. VALUE IN HEALTH, 2013, 16 (07) : A442 - A442
  • [38] Randomized, 1-year comparison of three ways to initiate and advance insulin for type 2 diabetes: twice-daily premixed insulin versus basal insulin with either basal-plus one prandial insulin or basal-bolus up to three prandial injections
    Riddle, M. C.
    Rosenstock, J.
    Vlajnic, A.
    Gao, L.
    [J]. DIABETES OBESITY & METABOLISM, 2014, 16 (05): : 396 - 402
  • [39] A 12-wk follow-up study to evaluate the effects of mixing insulin lispro and insulin glargine in young individuals with type 1 diabetes
    Lucchesi, Maria B. B.
    Komatsu, William R.
    Gabbay, Monica A. L.
    Dib, Sergio A.
    [J]. PEDIATRIC DIABETES, 2012, 13 (07) : 519 - 524
  • [40] Cost-effectiveness analysis of basal/bolus therapy in type-1 diabetes using insulin detemir plus insulin aspart or human soluble insulin-based basal/bolus regimens in Germany
    Valentine, WJ
    Wittrup-Jensen, KU
    Palmer, AJ
    Roze, S
    [J]. VALUE IN HEALTH, 2005, 8 (06) : A160 - A161